Klas E. Bratteby

Stockholm, AB 17177, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy.

Preclinical efficacy and dosimetry of CD44v6-directed terbium-161 radionuclide therapy.

Journal: Theranostics
Published: March 28, 2026

HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.

HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.

Journal: Frontiers in oncology
Published: February 17, 2026

Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody.

Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 04, 2025

Rapid fabrication and dissolution of pressed 58Ni/Mg matrix targets for 55Co production.

Rapid fabrication and dissolution of pressed 58Ni/Mg matrix targets for 55Co production.

Journal: EJNMMI radiopharmacy and chemistry
Published: November 21, 2024

GMP production of [18F]FE-PE2I on a TRACERLab FX2 N synthesis module, a radiotracer for in vivo PET imaging of the dopamine transport.

GMP production of [18F]FE-PE2I on a TRACERLab FX2 N synthesis module, a radiotracer for in vivo PET imaging of the dopamine transport.

Journal: EJNMMI radiopharmacy and chemistry
Published: March 25, 2024

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer.

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [68Ga]Ga-ABY-025 tracer.

Journal: EJNMMI radiopharmacy and chemistry
Published: October 13, 2023

The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.

The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.

Journal: Nature communications
Published: May 17, 2023

Development of 18F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging.

Development of 18F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 06, 2022

Development of the First Aliphatic 18F-Labeled Tetrazine Suitable for Pretargeted PET Imaging-Expanding the Bioorthogonal Tool Box.

Development of the First Aliphatic 18F-Labeled Tetrazine Suitable for Pretargeted PET Imaging-Expanding the Bioorthogonal Tool Box.

Journal: Journal of medicinal chemistry
Published: October 15, 2021

Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I.

Fully Automated GMP-Compliant Synthesis of [18F]FE-PE2I.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 26, 2021

Insights into Elution of Anion Exchange Cartridges: Opening the Path toward Aliphatic 18F-Radiolabeling of Base-Sensitive Tracers.

Insights into Elution of Anion Exchange Cartridges: Opening the Path toward Aliphatic 18F-Radiolabeling of Base-Sensitive Tracers.

Journal: ACS pharmacology & translational science
Published: May 12, 2021

Aliphatic 18 F-Radiofluorination: Recent Advances in the Labeling of Base-Sensitive Substrates*.

Aliphatic 18 F-Radiofluorination: Recent Advances in the Labeling of Base-Sensitive Substrates*.

Journal: ChemMedChem
Published: April 30, 2021
Showing 1-12 of 15

Last Updated: 09/26/2026